Predicting the duration of action of β2-adrenergic receptor agonists: Ligand and structure-based approaches

Mol Inform. 2023 Dec;42(12):e202300141. doi: 10.1002/minf.202300141. Epub 2023 Nov 9.

Abstract

Agonists of the β2 adrenergic receptor (ADRB2) are an important class of medications used for the treatment of respiratory diseases. They can be classified as short acting (SABA) or long acting (LABA), with each class playing a different role in patient management. In this work we explored both ligand-based and structure-based high-throughput approaches to classify β2-agonists based on their duration of action. A completely in-silico prediction pipeline using an AlphaFold generated structure was used for structure-based modelling. Our analysis identified the ligands' 3D structure and lipophilicity as the most relevant features for the prediction of the duration of action. Interaction-based methods were also able to select ligands with the desired duration of action, incorporating the bias directly in the structure-based drug discovery pipeline without the need for further processing.

Keywords: ADRB2; drug design; machine learning; molecular dynamics; molecular modelling.

MeSH terms

  • Adrenergic beta-2 Receptor Agonists* / pharmacology
  • Adrenergic beta-2 Receptor Agonists* / therapeutic use
  • Humans
  • Ligands

Substances

  • Ligands
  • Adrenergic beta-2 Receptor Agonists